Literature DB >> 9766667

Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin.

J N Sarkaria1, R S Tibbetts, E C Busby, A P Kennedy, D E Hill, R T Abraham.   

Abstract

Members of the phosphatidylinositol-3 kinase related kinase (PIKK) family function in both cell cycle progression and DNA damage-induced cell cycle checkpoints. The fungal metabolite, wortmannin, is an effective radiosensitizer that irreversibly inhibits certain members of the PIKK family. Based on their roles in DNA damage responses, several PIKKs, DNA-dependent protein kinase (DNA-PK), ataxia telangiectasia mutated (ATM) and the ataxia- and Rad3-related protein (ATR), are potential targets for the radiosensitizing effect of wortmannin. In this report, we demonstrate that wortmannin is a relatively potent inhibitor of DNA-PK (IC50, 16 nM) and ATM (IC50, 150 nM) activities, whereas ATR activity is significantly less sensitive to this drug (IC50, 1.8 microM). In intact A549 lung adenocarcinoma cells, wortmannin inhibited both DNA-PK and ATM at concentrations that correlated closely with those required for radiosensitization. Furthermore, pretreatment of A549 cells with wortmannin resulted in radioresistant DNA synthesis, a characteristic abnormality of ATM-deficient cells. These results identify wortmannin as an inhibitor of ATM activity and suggest that ATM and DNA-PK are relevant targets for the radiosensitizing effect of this drug in cancer cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9766667

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  173 in total

Review 1.  DNA replication blockade impairs p53-transactivation.

Authors:  R Takimoto; W S El-Deiry
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

2.  Purification and DNA binding properties of the ataxia-telangiectasia gene product ATM.

Authors:  G C Smith; R B Cary; N D Lakin; B C Hann; S H Teo; D J Chen; S P Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

3.  Phosphorylation and rapid relocalization of 53BP1 to nuclear foci upon DNA damage.

Authors:  L Anderson; C Henderson; Y Adachi
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

Review 4.  Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress.

Authors:  M Ljungman
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

5.  The influence of DNA double-strand break structure on end-joining in human cells.

Authors:  J Smith; C Baldeyron; I De Oliveira; M Sala-Trepat; D Papadopoulo
Journal:  Nucleic Acids Res       Date:  2001-12-01       Impact factor: 16.971

6.  UV-induced hyperphosphorylation of replication protein a depends on DNA replication and expression of ATM protein.

Authors:  G G Oakley; L I Loberg; J Yao; M A Risinger; R L Yunker; M Zernik-Kobak; K K Khanna; M F Lavin; M P Carty; K Dixon
Journal:  Mol Biol Cell       Date:  2001-05       Impact factor: 4.138

7.  DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.

Authors:  Stela S Palii; Beth O Van Emburgh; Umesh T Sankpal; Kevin D Brown; Keith D Robertson
Journal:  Mol Cell Biol       Date:  2007-11-08       Impact factor: 4.272

8.  Autophosphorylation of the DNA-dependent protein kinase catalytic subunit is required for rejoining of DNA double-strand breaks.

Authors:  Doug W Chan; Benjamin Ping-Chi Chen; Sheela Prithivirajsingh; Akihiro Kurimasa; Michael D Story; Jun Qin; David J Chen
Journal:  Genes Dev       Date:  2002-09-15       Impact factor: 11.361

Review 9.  The PIK3CA gene as a mutated target for cancer therapy.

Authors:  John P Gustin; David P Cosgrove; Ben Ho Park
Journal:  Curr Cancer Drug Targets       Date:  2008-12       Impact factor: 3.428

Review 10.  Clinically Applicable Inhibitors Impacting Genome Stability.

Authors:  Anu Prakash; Juan F Garcia-Moreno; James A L Brown; Emer Bourke
Journal:  Molecules       Date:  2018-05-13       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.